Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma

High-dose interleukin-2 (HD IL-2) was approved for treatment of metastatic renal cell carcinoma (mRCC) in 1992 and for metastatic melanoma (mM) in 1998, in an era predating targeted therapies and immune checkpoint inhibitors. The PROCLAIM(SM) registry was established to collect and analyze data for...

Descripción completa

Detalles Bibliográficos
Autores principales: Alva, Ajjai, Daniels, Gregory A., Wong, Michael K. K., Kaufman, Howard L., Morse, Michael A., McDermott, David F., Clark, Joseph I., Agarwala, Sanjiv S., Miletello, Gerald, Logan, Theodore F., Hauke, Ralph J., Curti, Brendan, Kirkwood, John M., Gonzalez, Rene, Amin, Asim, Fishman, Mayer, Agarwal, Neeraj, Lowder, James N., Hua, Hong, Aung, Sandra, Dutcher, Janice P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5099373/
https://www.ncbi.nlm.nih.gov/pubmed/27714434
http://dx.doi.org/10.1007/s00262-016-1910-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5099373/
https://www.ncbi.nlm.nih.gov/pubmed/27714434
http://dx.doi.org/10.1007/s00262-016-1910-x

Ejemplares similares